Cytosolix develops oral and intravenous formulations that specifically target tumor acidity to enhance the effectiveness of small molecule cancer therapies. By addressing the acidic microenvironment of tumors, these derivatives aim to improve therapeutic outcomes for cancer patients.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors exhibit an acidic microenvironment due to increased metabolic activity and poor perfusion, which can reduce the efficacy of chemotherapeutic drugs. This acidity can promote drug resistance, increase metastasis, and suppress immune responses within the tumor.
Solution
Cytosolix is developing pH-sensitive drug delivery systems that selectively target the acidic microenvironment of tumors to enhance the effectiveness of small molecule cancer therapies. Their oral and intravenous formulations are designed to release the therapeutic payload specifically within the tumor, maximizing drug concentration at the site of action while minimizing systemic toxicity. By neutralizing the acidic microenvironment, Cytosolix's approach aims to improve drug penetration, overcome drug resistance mechanisms, and enhance overall therapeutic outcomes for cancer patients. This targeted delivery strategy has the potential to improve the therapeutic index of existing cancer drugs and expand treatment options for patients with solid tumors.
Target Audience
The primary target audience includes pharmaceutical companies seeking to improve the efficacy and safety of their existing cancer therapies, as well as oncologists and cancer patients seeking more effective treatment options for solid tumors.
Features
- pH-sensitive drug release mechanism that triggers drug release in acidic conditions
- Oral and intravenous formulations for flexible administration
- Enhanced drug penetration into solid tumors
- Reduced systemic toxicity compared to conventional chemotherapy